Press Release, The Hague, 10 June 2021
EHA2021 Abstract S143 and EP631
The HARMONY Alliance will share new insights in Chronic Lymphocytic Leukemia (CLL) at the virtual Annual Congress of the European Hematology Association (EHA2021 from 9-17 June 2021). Dr Larry Mansouri of Karolinska Institutet will give an oral presentation and Dr Thomas Chatzikonstantinou of the European Research Initiative on CLL will give a poster presentation.
The clinical course of CLL is highly variable. Some patients will never require treatment whereas others will develop a treatment need over time. The disease is highly heterogeneous from a genomic perspective as well. A limited number of recurrently mutated genes are observed in more than 10% of patients, while hundreds of other genes have been found to be mutated in only in a fraction of patients. As a result, thousands of patients need to be studied to obtain robust insights into the role of these mutations in the course of the disease. The HARMONY Big Data Platform offers excellent opportunities to do just that.
At EHA2021, Dr Larry Mansouri of Karolinska Institutet (Sweden) will give an oral presentation about the results of a HARMONY research project that aimed to assess the clinical impact of recurrent gene mutations in CLL. Professor Richard Rosenquist Brandell was the principal investigator in this study.
Centers across Europe were asked to sequence the ten mostly commonly mutated genes in CLL in their patients. There has been fantastic interest, therefore the cohort now consists of more than 4,600 patients.
The frequency of the different mutations were studied. The team also studied the association of the genes with time-to-first-treatment and overall survival. This results may allow clinicians to give patients a more reliable estimate of what they can expect in terms of the clinical course of the disease. In addition, it may affect treatment choices.
Dr Thomas Chatzikonstantinou (European Research Initiative on CLL, INAB, CERTH, Thessaloniki, Greece) will present a poster about other malignancies in the history of CLL. The researchers retrospectively evaluated data from 13,808 patients from 64 centers. They report strong associations between the development of other hematological malignancies, especially MDS/AML, and certain biological features, as well as treatment for CLL, with a highly relevant risk for patients treated with CIT, particularly the FCR regimen.
In contrast, the development of solid tumors appeared unaffected by treatment administration, prompting further investigation in specific patient subgroups that will be presented at the congress.
The CLL presentations are made available as of Friday, June 11, 2021 (09:00 CEST). All EHA2021 sessions content will be accessible for on-demand viewing until August 15, 2021 on the virtual congress platform.
More information: Ellen de Waal, HARMONY Manager Communications and Dissemination, firstname.lastname@example.org
Receive the latest news. Click here to subscribe!